Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No modification of the beneficial effect of NSAIDs on colorectal cancer by CYP2C9 genotype.

The Netherlands journal of medicine - 1 Apr 2009

Siemes C, Eijgelsheim M, Dieleman J P, van Schaik R H N, Uitterlinden A G, van Duijn C M, Hofman A, Coebergh J W W, Stricker B H Ch, Visser L E

Abstract excerpt

BACKGROUND: CYP2C9 enzymes are involved in non-steroidal anti-inflammatory drug (NSAID) metabolism. Therefore, we investigated whether CYP2C9*2 and *3 variant alleles, encoding for enzymes with lower activity, increased the protective effect of NSAIDs on colorectal cancer. METHODS: Individual and combined associations of NSAIDs and CYP2C9*2 and *3 variant alleles with colorectal cancer were studied in 7757...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Anti-Inflammatory Agents, Non-Steroidal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Colorectal Neoplasms

Share to Cytochrome P-450 CYP2C9

Share to Netherlands

Share to Proportional Hazards Models

Share to Risk Factors

Source

Identifiers

PMID: 19581657

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No modification of the beneficial effect of NSAIDs on colorectal cancer by CYP2C9 genotype.PMID 19581657Read ↗

CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleedingSemantic proximity Read ↗

An update on the pharmacogenomics of NSAID metabolism and the risk of gastrointestinal bleeding.Semantic proximity Read ↗

No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma.Semantic proximity Read ↗

Protective effect of NSAIDs on cancer and influence of COX-2 C(-765G) genotype.Semantic proximity Read ↗

Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding.Semantic proximity Read ↗

Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention.Semantic proximity Read ↗

Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.Semantic proximity Read ↗

Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry.Semantic proximity Read ↗

Allele variants of the cytochrome P450 2C9 genotype in white subjects from The Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs.Semantic proximity Read ↗

Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.Semantic proximity Read ↗

Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?Semantic proximity Read ↗

Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.